Table 1.
Clinical characteristics of the study group
| Number or mean ± SD (range, median) | ||
|---|---|---|
| Subjects (n = 104) | Gestational age (week) | 29+1 (24+2–35+5, 29+4) |
| Birth weight (g) | 1210.5 ± 422.1 (520–2500, 1140) | |
| Birth height (cm) | 37.5 ± 4.6 (24.5–48.0, 37.5) | |
| Sex (male:female) | 58:46 | |
| CYP1A2*1C genotype (AA:AG:GG) | 11:39:54 | |
| CYP1A2*1F genotype (AA:AC:CC) | 47:45:12 | |
| Samples (n = 152) | Postmenstrual age (week) | 31+4 (25+3–37+1, 31+6) |
| Postnatal age (day) | 21.1 ± 17.7 (5–74, 12.5) | |
| Weight (g) | 1348.3 ± 443.0 (540–2900, 1335) | |
| Height (cm) | 38.6 ± 3.9 (24.5–48.0, 38.5) | |
| Route of administration (IV:PO) | 90:62 | |
| Dose of drug (mg kg−1 d−1) | 5.6 ± 1.5 (1.9–9.6, 5.4) | |
| Serum theophylline trough concentration (μg ml−1) | 7.96 ± 4.18 (0.90–22.33, 7.78) | |
| 24‐h urine output (ml kg−1 h−1) | 4.2 ± 1.1 (1.6–7.0, 4.1) | |
| Serum BUN (mg dl−1) | 11.1 ± 9.1 (1–47, 8) | |
| Serum Cr (mg dl−1) | 0.55 ± 0.22 (0.16–1.40, 0.53) | |
| Serum AST (IU/l) | 27.6 ± 21.1 (13–168, 22.5) | |
| Serum ALT (IU/l) | 9.1 ± 9.8 (0–83, 7) | |
| Serum protein (g dl−1) | 4.8 ± 0.6 (3.7–6.2, 4.7) | |
| Serum albumin (g dl−1) | 3.3 ± 0.4 (2.5–4.3, 3.3) | |
| Clearance of theophylline | Total clearance (ml kg−1 min−1) | 0.50 ± 0.29 (0.10–1.76, 0.36) |
| Renal clearance (ml kg−1 min−1) | 0.16 ± 0.06 (0.04–0.36, 0.15) | |
| Nonrenal clearance (ml kg−1 min−1) | 0.34 ± 0.28 (0.02–1.64, 0.22) |
IV, intravenous; PO, peroral; BUN, blood urea nitrogen; Cr, creatinine; AST, aspartate aminotransferase; ALT, alanine aminotransferase